The Cardiac Arrhythmia Suppression Trial

Robert J. Myerburg; Kenneth M. Kessler; Ronald J. Prineas; Jack L. Snitzer; John W. Fornace; Georg Schmidt; Kurt Ulm; Petra Barthel; John S. Flax; Andrew Cg Uprichard; A. David Canter; Jeremy N. Ruskin

doi:10.1056/NEJM198912213212510

The Cardiac Arrhythmia Suppression Trial

Robert J. Myerburg, Kenneth M. Kessler, Ronald J. Prineas, Jack L. Snitzer, John W. Fornace, Georg Schmidt, Kurt Ulm, Petra Barthel, John S. Flax, Andrew Cg Uprichard, A. David Canter, Jeremy N. Ruskin

Default

Research output: Contribution to journal › Letter › peer-review

21 Scopus citations

Abstract

To the Editor: Some proarrhythmia must be expected with the use of all antiarrhythmic drugs. The results of any antiarrhythmic drug trial should therefore be considered in terms of an antiarrhythmia-proarrhythmia equilibrium, with beneficial outcome being an expression of the extent to which antiarrhythmic efficacy exceeds deaths from proarrhythmia. The risk inherent to the study population, provided by mortality figures from the placebo groups, is a major factor in establishing the balance. The Multicenter PostInfarction Research Group study¹and the Cardiac Arrhythmia Pilot Study²provided meticulous preparation for an interventional trial, but the outcome of the Cardiac Arrhythmia Suppression Trial.Â .Â .

Original language	English
Pages (from-to)	1754-1756
Number of pages	3
Journal	New England Journal of Medicine
Volume	321
Issue number	25
DOIs	https://doi.org/10.1056/NEJM198912213212510
State	Published - 21 Dec 1989

Access to Document

10.1056/NEJM198912213212510

Cite this

@article{cf1cfa7538b842bca4b16ad617868ea5,

title = "The Cardiac Arrhythmia Suppression Trial",

abstract = "To the Editor: Some proarrhythmia must be expected with the use of all antiarrhythmic drugs. The results of any antiarrhythmic drug trial should therefore be considered in terms of an antiarrhythmia-proarrhythmia equilibrium, with beneficial outcome being an expression of the extent to which antiarrhythmic efficacy exceeds deaths from proarrhythmia. The risk inherent to the study population, provided by mortality figures from the placebo groups, is a major factor in establishing the balance. The Multicenter PostInfarction Research Group study1and the Cardiac Arrhythmia Pilot Study2provided meticulous preparation for an interventional trial, but the outcome of the Cardiac Arrhythmia Suppression Trial.{\^A} .{\^A} .",

author = "Myerburg, {Robert J.} and Kessler, {Kenneth M.} and Prineas, {Ronald J.} and Snitzer, {Jack L.} and Fornace, {John W.} and Georg Schmidt and Kurt Ulm and Petra Barthel and Flax, {John S.} and Uprichard, {Andrew Cg} and Canter, {A. David} and Ruskin, {Jeremy N.}",

year = "1989",

month = dec,

day = "21",

doi = "10.1056/NEJM198912213212510",

language = "English",

volume = "321",

pages = "1754--1756",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "25",

}

TY - JOUR

T1 - The Cardiac Arrhythmia Suppression Trial

AU - Myerburg, Robert J.

AU - Kessler, Kenneth M.

AU - Prineas, Ronald J.

AU - Snitzer, Jack L.

AU - Fornace, John W.

AU - Schmidt, Georg

AU - Ulm, Kurt

AU - Barthel, Petra

AU - Flax, John S.

AU - Uprichard, Andrew Cg

AU - Canter, A. David

AU - Ruskin, Jeremy N.

PY - 1989/12/21

Y1 - 1989/12/21

N2 - To the Editor: Some proarrhythmia must be expected with the use of all antiarrhythmic drugs. The results of any antiarrhythmic drug trial should therefore be considered in terms of an antiarrhythmia-proarrhythmia equilibrium, with beneficial outcome being an expression of the extent to which antiarrhythmic efficacy exceeds deaths from proarrhythmia. The risk inherent to the study population, provided by mortality figures from the placebo groups, is a major factor in establishing the balance. The Multicenter PostInfarction Research Group study1and the Cardiac Arrhythmia Pilot Study2provided meticulous preparation for an interventional trial, but the outcome of the Cardiac Arrhythmia Suppression Trial.Â .Â .

AB - To the Editor: Some proarrhythmia must be expected with the use of all antiarrhythmic drugs. The results of any antiarrhythmic drug trial should therefore be considered in terms of an antiarrhythmia-proarrhythmia equilibrium, with beneficial outcome being an expression of the extent to which antiarrhythmic efficacy exceeds deaths from proarrhythmia. The risk inherent to the study population, provided by mortality figures from the placebo groups, is a major factor in establishing the balance. The Multicenter PostInfarction Research Group study1and the Cardiac Arrhythmia Pilot Study2provided meticulous preparation for an interventional trial, but the outcome of the Cardiac Arrhythmia Suppression Trial.Â .Â .

UR - http://www.scopus.com/inward/record.url?scp=0024819537&partnerID=8YFLogxK

U2 - 10.1056/NEJM198912213212510

DO - 10.1056/NEJM198912213212510

M3 - Letter

C2 - 2535645

AN - SCOPUS:0024819537

SN - 0028-4793

VL - 321

SP - 1754

EP - 1756

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 25

ER -

The Cardiac Arrhythmia Suppression Trial

Abstract

Access to Document

Other files and links

Fingerprint

Cite this